Catalyst
Slingshot members are tracking this event:
AstraZeneca (AZN) releases positive results from a Phase 3 trial OLYMPIAD, which evaluates LYNPARZA (olaparib) in treating HER2-negative, BRCA1- or BRCA2-positive breast cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 17, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Olympiad, Phase 3, Lynparza, Olaparib, Her2-negative, Brca Breast Cancer
